The invitation only group represents a collective of companies at the forefront of ethical technological and business model innovation working on solutions to our world's most significant challenges
/PRNewswire/ BenevolentAI, a leading clinical-stage artificial intelligence (AI) enabled drug discovery company, today announced that it has joined the.
- The collaboration will use AI to identify potential biological targets and therapies that could be repurposed for dengue to prevent disease progression - Dengue is a climate-sensitive
/PRNewswire/ BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca,.
/PRNewswire/ BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca,.